Trial of Moxifloxacin-containing Triple Therapy after Initial and Second-line Treatment Failures for Helicobacter pylori Infection / 대한소화기학회지
The Korean Journal of Gastroenterology
;
: 111-117, 2005.
Artículo
en Coreano
| WPRIM
| ID: wpr-84686
ABSTRACT
BACKGROUND/AIMS:
Proton-pump inhibitor (PPI)-based triple therapy for Helicobacter pylori eradication is widely used with considerable failure rate. Bismuth-based, second-line therapy is also associated with failures in more than 20% of cases in Korea. Our aim was to evaluate the efficacy and tolerability of third-line therapy containing moxifloxacin as a rescue in Korea.METHODS:
The subjects consisted of 201 patients infected with H. pylori, who were treated with PPI-based therapy, 42 patients treated with bismuth-based after failure of initial PPI triple therapy, and 10 patients treated with moxifloxacin-containing triple therapy after failure of successive initial and second-line therapy. Eradication rate, compliance and side effect rates were compared.RESULTS:
The eradication rates of initial, second-line, and third-line therapy were as follows 67.2%/83.3%, 54.8%/76.7%, 80.0%/88.9% by intention-to-treat and per protocol analysis, respectively. The compliance of patients for each treatment was 98.2%, 90.9%, 100%, respectively. The side effect rate was significantly higher in the bismuth triple therapy than in the PPI- or moxifloxacin-containing triple therapy (p<0.05).CONCLUSIONS:
Moxifloxacin-containing triple therapy shows high eradication rate with fewer side effects and good compliance. Thus, this regimen could be used as a rescue therapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Quinolinas
/
Compuestos Aza
/
Bismuto
/
Helicobacter pylori
/
Infecciones por Helicobacter
/
Bombas de Protones
/
Quimioterapia Combinada
/
Antiácidos
/
Antibacterianos
Tipo de estudio:
Guía de Práctica Clínica
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
/
Masculino
Idioma:
Coreano
Revista:
The Korean Journal of Gastroenterology
Año:
2005
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS